Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation

Bone Marrow Transplant. 2020 Jun;55(6):1191-1193. doi: 10.1038/s41409-019-0664-4. Epub 2019 Sep 3.

Authors

Christina Rautenberg¹, Jennifer Kaivers¹, Ulrich Germing¹, Rainer Haas¹, Stefanie Ackerstaff², Till Hoffmann², Guido Kobbe¹, Thomas Schroeder³

Affiliations

¹ Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.
² Institute for Transplantation Diagnostics and Cell Therapeutics, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany.
³ Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Duesseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de.

PMID: 31481799
DOI: 10.1038/s41409-019-0664-4

No abstract available

Publication types

Letter

MeSH terms

ABO Blood-Group System
Antibodies, Monoclonal
Blood Group Incompatibility
Hematopoietic Stem Cell Transplantation*
Humans
Red-Cell Aplasia, Pure* / drug therapy
Red-Cell Aplasia, Pure* / etiology

Substances

ABO Blood-Group System
Antibodies, Monoclonal
daratumumab